Expression of the transcription factor ETS2 in brain of patients with Down Syndrome - Evidence against the overexpression-gene dosage hypothesis

Journal of Neural Transmission, Supplement

Volumn , Issue 57, 1999, Pages 269-281

  Greber Platzer, S ^a   Schatzmann Turhani, D ^a   Cairns, N ^b   Balcz, B ^a   Lubec, G ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; MESSENGER RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ETS2; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; ERF PROTEIN, HUMAN; ETS2 PROTEIN, HUMAN; ONCOPROTEIN; PRIMER DNA; REPRESSOR PROTEIN; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR ETS 2;

ADULT; AGED; ARTICLE; BRAIN REGION; CEREBELLUM; CHROMOSOME 21; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN SYNDROME; FEMALE; FRONTAL LOBE; GENE DOSAGE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; MALE; NERVE CELL PLASTICITY; NERVE DEGENERATION; OCCIPITAL LOBE; PARIETAL LOBE; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; BRAIN; CHROMOSOME MAP; GENETICS; METABOLISM; METHODOLOGY; MIDDLE AGED; NUCLEOTIDE SEQUENCE; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; BASE SEQUENCE; BRAIN; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 21; DNA PRIMERS; DNA-BINDING PROTEINS; DOWN SYNDROME; FEMALE; GENE DOSAGE; HUMANS; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEIN C-ETS-2; PROTO-ONCOGENE PROTEINS; REFERENCE VALUES; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS;

EID: 0032585828     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-7091-6380-1_18     Document Type: Article

References (19)

1. Bhat NK, Fisher RJ, Fujiwara S, Ascione R, Papas TS (1987) Temporal and tissue-specific expression of mouse ets genes. Proc Natl Acad Sci USA 84: 3161-3165
2. Burke WJ, O'Malleay KL, Chung HD, Harmon SK, Miller JP, Berg L (1991) Effect of pre-and postmortem variables on specific mRNA levels in human brain. Brain Res Mol Brain Res 11(1): 37-41
3. Epstein CJ, Korenberg JR, Anneren G, Antonarakis SE, Ayme S, Courchesne E, Epstein LB, Fowler A, Groner Y, Huret JL, Kemper TI, Lott IT, Lubin BH, Magenis E, Opitz JM, Patterson D, Priest JH, Pueschel SM, Rapoport SI, Sinet PM, Tanzi RE, de la Cruz F (1991) Protocols to establisch genotype-phenotype correlations in Down syndrome. Am J Hum Genet 49: 207-235
4. Greber-Platzer S, Schatzmann-Turhani D, Wollenek G, Lubec G (1999) Evidence against the current hypothesis of "gene dosage effects" of trisomy 21: ets-2, encoded on chromosome 21 is not overexpressed in hearts of patients with Down Syndrome. Biochem Biophys Res Comm (in press)
5. Huret JL, Delabar JM, Marlhens F, Aurias A, Nicole A, Berthier M, Tanzer J, Sinet PM (1987) Down syndrome with duplication of a region of chromosome 21 containing the CuZn superoxide dismutase gene without detectable karyotypic abnormality. Hum Genet 75: 251-257
6. Huret JL, Leonard C, Chery M, Phillipe C, Shafei-Benaissa E, Lefaure G, Labrune B, Gilgenkranzt S (1995) Monosomy 21 q: two cases of del (21q) and review of the literaure. Clin Genet 48: 140-147
7. Kola I, Christiano F, de Haan JB, Thomas R, Sumarsono S, Corrick CM, Tymms M (1995) Genes, embryogenesis and Down Syndrome. In: Moeloek FA, Affandi B, Trounson AO (eds) Advances in human reproduction. Casterton-Parthenon, NY, pp 309-320
8. Korenberg JR, Chen XN, Schipper R, Sun Z, Gonsky R, Gerwehr S, Carpenter N, Daumer C, Dignan P, Disteche C, Graham JM, Hugdins L, McGillivray B, Miyazaki K, Ogasawara N, Park JP, Pagon R, Pueschel S, Sack G, Say B, Schuffenhauer S, Soukup S, Yamanaka T (1994) Down syndrome phenotypes: the consequences of chromosomal imbalance. Proc Natl Acad Scei USA 91: 4997-5001
9. Kumar AJ, Naidich TP, Stetten G, et al (1992) Chromosomal disorders: background and neuroradiology. AJNR Am J Neuroradiol 13: 577-593
10. Lott IT (1992) The neurology of Alzheimer disease in Down Syndrome. Prog Clin Biol Res 379: 1-14
11. Maraoulakou IG, Papas TS, Green JE (1994) Differential expression of ets-1 and ets-2 proto-oncogenes during murine embryogenesis. Oncogene 9: 1551-1565
12. Rychlik W, Rhoads RE (1989) A computer program for choosing optimal oligonucletide primers for filter hybridization, sequencing and in vitro amplification. Nucl Acids Res 17: 8543-8551
13. Schatzmann-Turhani D, Greber-Platzer S, Cairns N, Lubec G (1999) Determination of the protooncogene ets-2 gene transcript in human brain at the attogram-level by the use of competitive RT/PCR. Amino Acids (in press)
14. Seidl R, Gerber S, Schuller E, Bernert G, Cairns N, Lubec G (1997) Evidence against increased oxidative DNA-damabe in Down syndrome. Neurosci Lett 235: 137-140
15. Shapiro BL (1994) The environmental basis of the Down Syndrome phenotype. Dev Med Child Neurol 36(1): 84-90
16. Shen JJ, Williams BJ, Zipursky A, Doyle J, Sherman SL, Jabobs PA, Shugar AL, Soukoup SW, Hassold TJ (1995) Cytogenetic and molecular studies of Down syndrome individuals with leukemia. Am J Hum Genet 56: 915-9254
17. Sinet PM, Theophile D, Rahmani Z, Chettouh Z, Blouin JL, Prieur M, Noel B, Delabar JM (1994) Mapping of the Down Syndrome phenotype on chormosome 21 at the molecular level. Biomed Pharmacother 48: 247-252
18. Sumarsono SH, Wilson TJ, Tymms MF, Venter DJ, Corrick CM (1996) Down's syndrome-like skeletal abnormalities in Ets 2 transgenic mice. Nature 379: 534-537
19. Wasylyk B, Hahn SL, Giovane A (1993) The Ets family transcription factors. Eur J Biochem 211(1-2): 7-18